Twenty percent of women with endometrial cancer will die from it, predominantly from systemic spread. Chemotherapy is, therefore, needed both for “high risk” women at diagnosis (stages III and IV–all histologies; stage II Clear Cell or grade 3; Papillary Serous or MMMT, irrespective of stage) and for relapsers, unless grade 1, when hormones are a preferable initial option. The most active single agents are: the anthracyclines, taxanes and platins; response rates 17–37, 21–67 and 13–14%, respectively. Combinations have proven to be superior in terms of relapse but not survival. Taxane-/platin-containing regimens are the phase III proven best combinations.